Purpose: H. pylori infection is a common cause of gastritis, peptic ulcers, and gastric cancer, making early detection and treatment critical. Test-and-treat models—where patients are screened and immediately treated if positive—have become a key strategy in managing H. pylori-related diseases. This area presents strong business opportunities for diagnostic companies, pharmaceutical firms, gastroenterology clinics, and healthcare service providers.
Upload here: https://gastroenterology-hepatology.utilitarianevents.com/upload-presentation/
WhatsApp: https://wa.me/+971551792927
Email: info-ucg@utilitarianconferences.com
Keynote Points:
High prevalence of H. pylori infection globally
Demand for rapid, accurate, and non-invasive diagnostic tests
Opportunities in antibiotics, combination therapies, and treatment kits
Test-and-treat models reduce healthcare costs and improve patient compliance
Potential integration with telemedicine, digital tracking, and patient education platforms
Collaboration opportunities with hospitals, clinics, and laboratory networks
Increasing awareness campaigns driving early detection and preventive care
Benefits:
Access to a large, recurring patient base with digestive disorders
Strong ROI potential through diagnostics, treatment kits, and preventive programs
Differentiation through innovative, patient-centric care models
Supports preventive healthcare initiatives and public health campaigns
Opportunities for partnerships across pharma, diagnostics, and digital health
Long-term growth potential with scalable, standardized test-and-treat solutions